Skip to content

    OneSource Speci.

    ONESOURCEGood
    Healthcare·6 May 2025
    Management Summary

    OneSource delivered a transformative FY25, characterized by a 30% revenue jump and a doubling of EBITDA. The company is successfully pivoting toward high-value Drug Device Combinations (DDC), with 50 projects currently in the pipeline. While FY26 is signaled as a 'transition year' due to the timing of patent expiries for Semaglutide, management remains highly confident in achieving its $400 million revenue target by FY28.

    Highlights

    7

    • Full year FY25 revenue exceeded ₹1,445 crores, representing 30% YoY growth.

    • FY25 EBITDA reached ₹466.5 crores, more than doubling from FY24 levels.

    • Q4 FY25 EBITDA margin stood at a robust 43%, driven by high-margin Drug Device Combination (DDC) projects.

    • Management reaffirmed FY28 guidance of $400 million revenue with 38-40% EBITDA margins.

    • The company added 15 new customers in FY25, bringing the total logo count to over 70.

    • Net debt was significantly reduced to ₹4,707 million, with a target to be net debt-free in 2-3 years.

    • Capacity expansion is on track to reach 90 million units by December 2025 from the current 40 million.

    Key financials

    Single quarter

    06 metrics
    1. 01Revenue14,449 Mn+30%YoY
    2. 02Operating EBITDA4,665 Mn+100%YoY
    3. 03Adjusted PAT936 Mn
    4. 04EBITDA Margin43%
    5. 05EPS₹21.4

    Guidance & targets

    5
    CategoryTargetPriority
    Revenue
    Total Revenue
    $400 million
    		High
    Margin
    EBITDA Margin
    38-40%
    		High
    Capacity
    Rated Capacity
    90 million
    		High
    Debt
    Net Debt
    Debt Free
    		Medium
    Capex
    Capacity Expansion Investment
    $100 million
    		High

    Risks & concerns

    5
    RiskSeverity

    FY26 Transition Year Lumpiness

    Bulk of revenue growth from DDC commercial sales will only start in Q4 FY26 due to patent expiry timelines, leading to a 'tepid' H1 FY26. — Management acknowledged

    medium

    US FDA Observations

    One site received 4 observations (Form 483) on March 29; management claims they are 'norm' and already responded to. — Analyst downplayed

    medium

    Competition from Oral Formulations

    Management believes injectables will remain preferred for efficacy and lower 'pill burden' (once-a-week vs daily). — Analyst downplayed

    low

    Areas of Evasion(2)

    • Specific revenue breakdown for the DDC segment
    • Exact number of planned commercial launches in FY26

    Q&A highlights

    3

    “we are not specifically giving DDC number. But I think we have very clearly mentioned that... we are close to about 50 DDC projects.”

    Investors are keen to understand the exact margin profile of the DDC segment, which management is keeping aggregated for now.

    asked by Amey, JM Financial

    2 min read5 chapters

    Detailed Narrative

    01

    Record Financial Performance in FY25

    OneSource Specialty Pharma reported a stellar FY25 with revenues crossing ₹14,449 million, a 30% increase YoY. The operating EBITDA grew by 79% in Q4 alone, reaching ₹1,825 million, while the full-year EBITDA of ₹4,665 million was more than double the previous year. This growth was underpinned by strong execution of contracts and the onboarding of 15 new customers, bringing the total to over 70 logos.

    02

    FY26 as a Strategic Transition Year

    Management explicitly labeled FY26 as a transition year, cautioning that H1 FY26 might appear 'tepid' compared to a strong H2. This is primarily due to the timing of Semaglutide patent expiries, which are concentrated in March 2026. Consequently, commercial supplies for DDC products are expected to ramp up significantly only in Q4 FY26, mirroring the 'lumpy' performance seen in FY25.

    03

    Dominance in Drug-Device Combinations (DDC)

    The DDC segment is the primary growth engine, with approximately 50 projects currently in various stages of execution. Management highlighted that they have 20+ customers specifically for DDC, and the Q4 EBITDA margin of 43% reflects the high-value nature of these Master Service Agreement (MSA) executions. They are currently focusing on existing customers to avoid capacity clashes, given the high demand for GLP-1 and other self-administered injectables.

    04

    Aggressive Capacity Expansion and Capex

    To meet the anticipated surge in demand for GLP-1 generics, OneSource is expanding its rated capacity from 40 million units to over 90 million units by December 2025. The company plans to invest approximately $100 million in capex over the next two years. Furthermore, management teased a long-term plan to reach 220 million units of capacity, primarily located in India but with potential for inorganic global expansion.

    05

    De-leveraging and Balance Sheet Strength

    The company made significant strides in treasury operations, reducing net debt to ₹4,707 million by the end of the quarter. CFO Anurag Bhagania noted that high-cost debt was prepaid, reducing interest costs by 20% quarter-over-quarter. The company aims to maintain a debt-to-EBITDA ratio below 1.5x and intends to be completely net debt-free within the next 2 to 3 years.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.